A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

Experts in the neuropsychiatry drug development space say targeting the right patient population will be key for success in ...

LUCIDITY enrolled 598 patients early to mild/moderate Alzheimer's, half of whom were ... of Biogen/Eisai's pathfinder amyloid drug Aduhelm (aducanumab) on mixed data. For now, TauRx is upbeat ...

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease ... first amyloid-targeting drug Aduhelm (aducanumab), which was approved in the ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

An 80-something patient came in for an annual visit recently and was worried that recent memory lapses might be symptoms of Alzheimer’s disease. This patient, like several others in my practice ...

LOS ANGELES, Calif. (KABC) -- The Alzheimer's Association is inviting Los Angeles residents to join the fight to end Alzheimer's by participating in the Alzheimer's Association Walk to End ...